<DOC>
	<DOC>NCT01467323</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and safety of biphasic insulin aspart 30 in subjects with type 1 or type 2 diabetes.</brief_summary>
	<brief_title>Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Subjects with insulin requiring type 1 or type 2 diabetes for at least 24 months Current treatment with human insulin (either premix of short and long/intermediate acting insulin) in a twice daily treatment regimen preparation and/or selfmix for at least 12 months Body mass index (BMI) below or equal to 35.0 kg/m^2 HbA1c below or equal to 11.0% Total daily insulin dose at least 1.4 IU/kg Treatment with oral hypoglycaemic agents within the month prior to inclusion Recurrent severe hypoglycaemia (as judged by the investigator) Active proliferative retinopathy Impaired renal function with creatinine at least 150 mcmol/l (1.7 mg/dl) History of pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>